"Nafamostat has shown promising data against SARS-CoV-2 in vitro"- Dilip Shanghvi
India, June 2 -- "Sun Pharma is constantly evaluating potential targets that can be explored for treating Covid-19 patients. Nafamostat has shown promising data against SARS-CoV-2 virus in in vitro studies conducted by three independent groups of scientists in Europe, Japan and South Korea. We believe it holds promise in the treatment of COVID-19 patients."
- Dilip Shanghvi, Managing Director, Sun Pharma, Mumbai
Published by HT Digital Content Services with permission from BioSpectrum India....
Click here to read full article from source
To read the full article or to get the complete feed from this publication, please
Contact Us.